KEYNOTE-024 更新分析:帕博利珠单抗对比铂类化疗用于 PD-L1 肿瘤比例评分≥50% 的晚期非小细胞肺癌
这项随机、开放标签的 III 期 KEYNOTE-024 研究更新分析显示,在 PD-L1 肿瘤比例评分≥50% 且无 EGFR/ALK 异常的初治晚期非小细胞肺癌患者中,帕博利珠单抗较铂类化疗显著改善总生存(中位 OS 30.0 个月 vs 14.2 个月;HR 0.63,95%CI 0.47-0.86)。交叉调整后 HR 为 0.49(95%CI 0.34-0.69)。帕博利珠单抗组治疗相关 3-5 级不良事件发生率低于化疗组(31.2% vs 53.3%)。
要点
- 帕博利珠单抗组中位 OS 30.0 个月,化疗组 14.2 个月,HR 0.63(95%CI 0.47-0.86)。
- 化疗组 82 例交叉接受帕博利珠单抗,交叉调整后 OS 的 HR 为 0.49(95%CI 0.34-0.69)。
- 帕博利珠单抗组治疗相关 3-5 级不良事件发生率 31.2%,低于化疗组的 53.3%。
核心结论
- 延长随访后,一线帕博利珠单抗单药在无 EGFR/ALK 异常的初治晚期 NSCLC 患者中,尽管对照组交叉接受帕博利珠单抗作为后续治疗,仍持续显示较化疗的总生存获益。
研究设计与样本
- 随机、开放标签、III 期 KEYNOTE-024 研究,共随机分配 305 例患者(帕博利珠单抗组 n=154,化疗组 n=151)。
- 帕博利珠单抗 200 mg 每 3 周一次,最多 2 年;化疗为研究者选择的铂类方案 4-6 个周期。
- 化疗组患者在符合条件后可交叉接受帕博利珠单抗。
- 主要终点为无进展生存,总生存为重要的关键次要终点。
- 交叉调整分析采用简化两阶段法、秩保持结构失效时间和逆概率删失加权三种方法。
主要发现
- 数据截止日期为 2017 年 7 月 10 日,中位随访 25.2 个月;帕博利珠单抗组 73 例死亡,化疗组 96 例死亡。
- 帕博利珠单抗组中位 OS 为 30.0 个月(95%CI 18.3 个月至未达到),化疗组为 14.2 个月(95%CI 9.8-19.0 个月),HR 0.63(95%CI 0.47-0.86)。
- 化疗组有 82 例患者在研究内交叉接受帕博利珠单抗。
- 采用两阶段法进行交叉调整后,帕博利珠单抗对比化疗的 OS 的 HR 为 0.49(95%CI 0.34-0.69);秩保持结构失效时间和逆概率删失加权法的结果相似。
- 帕博利珠单抗组治疗相关 3-5 级不良事件发生率为 31.2%,化疗组为 53.3%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with a programmed death ligand 1 tumor proportion score of 50% or greater and without EGFR/ALK aberrations. We report an updated OS and tolerability analysis, including analyses adjusting for potential bias introduced by crossover from chemotherapy to pembrolizumab. PATIENTS AND METHODS: Patients were randomly assigned to pembrolizumab 200 mg every 3 weeks (for up to 2 years) or investigator's choice of platinum-based chemotherapy (four to six cycles). Patients assigned to chemotherapy could cross over to pembrolizumab upon meeting eligibility criteria. The primary end point was progression-free survival; OS was an important key secondary end point. Crossover adjustment analysis was done using the following three methods: simplified two-stage method, rank-preserving structural failure time, and inverse probability of censoring weighting. RESULTS: Three hundred five patients were randomly assigned (pembrolizumab, n = 154; chemotherapy, n = 151). At data cutoff (July 10, 2017; median follow-up, 25.2 months), 73 patients in the pembrolizumab arm and 96 in the chemotherapy arm had died. Median OS was 30.0 months (95% CI, 18.3 months to not reached) with pembrolizumab and 14.2 months (95% CI, 9.8 to 19.0 months) with chemotherapy (hazard ratio, 0.63; 95% CI, 0.47 to 0.86). Eighty-two patients assigned to chemotherapy crossed over on study to receive pembrolizumab. When adjusted for crossover using the two-stage method, the hazard ratio for OS for pembrolizumab versus chemotherapy was 0.49 (95% CI, 0.34 to 0.69); results using rank-preserving structural failure time and inverse probability of censoring weighting were similar. Treatment-related grade 3 to 5 adverse events were less frequent with pembrolizumab compared with chemotherapy (31.2% v 53.3%, respectively). CONCLUSION: With prolonged follow-up, first-line pembrolizumab monotherapy continues to demonstrate an OS benefit over chemotherapy in patients with previously untreated, advanced NSCLC without EGFR/ALK aberrations, despite crossover from the control arm to pembrolizumab as subsequent therapy.
引用
- Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol. 2019. PMID: 30620668. doi:10.1200/JCO.18.00149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。